BRPI0516398A - método de terapia de manutenção, métodos de tratamento, método para prevenir a recorrência da acne vulgar e usos de adapaleno - Google Patents

método de terapia de manutenção, métodos de tratamento, método para prevenir a recorrência da acne vulgar e usos de adapaleno

Info

Publication number
BRPI0516398A
BRPI0516398A BRPI0516398-6A BRPI0516398A BRPI0516398A BR PI0516398 A BRPI0516398 A BR PI0516398A BR PI0516398 A BRPI0516398 A BR PI0516398A BR PI0516398 A BRPI0516398 A BR PI0516398A
Authority
BR
Brazil
Prior art keywords
adapalene
maintenance therapy
treatment methods
acne vulgaris
prevent recurrence
Prior art date
Application number
BRPI0516398-6A
Other languages
English (en)
Inventor
Stephane Arsonnaud
Pascale Soto
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of BRPI0516398A publication Critical patent/BRPI0516398A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

MéTODO DE TERAPIA DE MANUTENçãO, MéTODOS DE TRATAMENTO, MéTODO PARA PREVENIR A RECORRêNCIA DA ACNE VULGAR E USOS DE ADAPALENO. A presente invenção trata de um méotdo de uso de adapaleno para a terapia de manutenção da acne vulgar para prevenir a recorrência da acne ou reduzir a severidade da recorrência da acne.
BRPI0516398-6A 2004-10-20 2005-10-20 método de terapia de manutenção, métodos de tratamento, método para prevenir a recorrência da acne vulgar e usos de adapaleno BRPI0516398A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62056404P 2004-10-20 2004-10-20
US11/009,024 US20060128808A1 (en) 2004-10-20 2004-12-13 Method of using adapalene in acne maintenance therapy
PCT/EP2005/012344 WO2006045640A1 (en) 2004-10-20 2005-10-20 Method of using adapalene in acne maintenance therapy

Publications (1)

Publication Number Publication Date
BRPI0516398A true BRPI0516398A (pt) 2008-09-02

Family

ID=35695580

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516398-6A BRPI0516398A (pt) 2004-10-20 2005-10-20 método de terapia de manutenção, métodos de tratamento, método para prevenir a recorrência da acne vulgar e usos de adapaleno

Country Status (11)

Country Link
US (1) US20060128808A1 (pt)
EP (1) EP1804783A1 (pt)
JP (1) JP2008517031A (pt)
KR (1) KR20070067198A (pt)
CN (1) CN101076326A (pt)
AU (1) AU2005298791B2 (pt)
BR (1) BRPI0516398A (pt)
CA (1) CA2583446A1 (pt)
MX (1) MX2007004586A (pt)
RU (1) RU2413509C2 (pt)
WO (1) WO2006045640A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820186B2 (en) 2001-12-21 2010-10-26 Galderma Research & Development Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
EA015815B1 (ru) 2005-08-02 2011-12-30 Сол-Джел Текнолоджиз Лтд. Покрытие из оксида металла для водонерастворимых ингредиентов
FR2894820B1 (fr) * 2005-12-15 2008-02-29 Galderma Res & Dev Compositions comprenant au moins un compose retinoide et au moins un compose anti-irritant et leurs utilisations
FR2903603B1 (fr) 2006-07-13 2009-03-20 Galderma Res & Dev S N C Snc Combinaison d'adapalene et de peroxyde de benzole dans le traitement de l'acne
US8080537B2 (en) 2006-07-13 2011-12-20 Galderma Research & Development Combinations of adapalene and benzoyl peroxide for treating acne lesions
US9149490B2 (en) * 2006-10-20 2015-10-06 Skinvisible Pharmaceuticals, Inc. Acne treatment composition and methods for using
ITBS20060194A1 (it) * 2006-11-08 2008-05-09 Paoli Ambrosi Gianfranco De Composizione per un trattamento farmaceutico a base di trietil citrato e adapalene
FR2910321B1 (fr) 2006-12-21 2009-07-10 Galderma Res & Dev S N C Snc Gel creme comprenant au moins un retinoide et du peroxyde de benzole
FR2910320B1 (fr) * 2006-12-21 2009-02-13 Galderma Res & Dev S N C Snc Emulsion comprenant au moins un retinoide et du peroxyde de benzole
CA2677167A1 (en) * 2007-01-30 2008-08-07 Galderma Research & Development Use of adapalene and benzoyl peroxide for the long term treatment of acne vulgaris
CA2677185C (en) 2007-02-01 2013-12-03 Ofer Toledano Method for preparing particles comprising metal oxide coating and particles with metal oxide coating
FR2916975B1 (fr) * 2007-06-11 2009-09-04 Galderma Res & Dev Compositions comprenant au moins un compose retinoide, un compose anti-irritant et du peroxyde de benzoyle, et leurs utilisations
FR2916966B1 (fr) * 2007-06-11 2011-01-14 Galderma Res & Dev Compositions comprenant au moins un compose retinoide, un compose anti-irritant et du peroxyde de benzoyle, et leurs utilisations
EP2288349A1 (en) * 2008-05-16 2011-03-02 Galderma Research & Development Therapy regimen for treating acne related diseases
WO2009141406A1 (en) * 2008-05-21 2009-11-26 Galderma Research & Development Maintenance therapy regimen for treating acne
AU2010203166A1 (en) * 2009-01-05 2010-07-08 Sol-Gel Technologies Ltd. Topical compositions containing coated active agents
US9687465B2 (en) 2012-11-27 2017-06-27 Sol-Gel Technologies Ltd. Compositions for the treatment of rosacea
RU2583559C2 (ru) * 2014-04-09 2016-05-10 государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) Средство и способ местного лечения папуло-пустулезной формы розацеа
CN110869013A (zh) 2017-07-12 2020-03-06 索尔-格尔科技有限公司 包含囊封的维甲酸的组合物
JP2021532155A (ja) * 2018-08-01 2021-11-25 タリス バイオメディカル エルエルシー トロスピウムを使用した過活動膀胱の治療方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2115418C1 (ru) * 1998-01-23 1998-07-20 Анатолий Владимирович Толстов Комбинированное химиотерапевтическое средство "бутол" для лечения местной раневой инфекции и воспалительных заболеваний
EP1532974B1 (en) * 2002-03-12 2008-12-17 Galderma Research & Development Composition comprising 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
RU2221570C1 (ru) * 2002-05-07 2004-01-20 Глубокова Ирина Борисовна Способ лечения акне

Also Published As

Publication number Publication date
RU2007118663A (ru) 2008-11-27
US20060128808A1 (en) 2006-06-15
RU2413509C2 (ru) 2011-03-10
EP1804783A1 (en) 2007-07-11
WO2006045640A1 (en) 2006-05-04
JP2008517031A (ja) 2008-05-22
AU2005298791B2 (en) 2011-04-14
MX2007004586A (es) 2007-10-05
CN101076326A (zh) 2007-11-21
KR20070067198A (ko) 2007-06-27
AU2005298791A1 (en) 2006-05-04
CA2583446A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
BRPI0516398A (pt) método de terapia de manutenção, métodos de tratamento, método para prevenir a recorrência da acne vulgar e usos de adapaleno
MX2007000611A (es) Tratamiento de la piel con luz y un agente benefico para mitigar el acne.
PH12017500930A1 (en) Hsp90 inhibitor combinations
WO2008036846A3 (en) Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
BRPI0417493B8 (pt) uso de uma toxina botulínica para tratamento de distúrbios da pele
AU2008232453A8 (en) Methods and compositions for reduction of side effects of therapeutic treatments
BRPI0510617A (pt) uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
CL2008003653A1 (es) Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
TW200745109A (en) Pyrrolo-pyridine kinase modulators
BRPI0713288A2 (pt) composiÇÕes de limpeza e/ou de tratamento que compreendem alfa-amilases mutantes
BRPI0413582B8 (pt) compostos, composições e métodos para inibir a atividade de proteasome
TNSN08400A1 (en) Organic compounds and their uses
MY162986A (en) Transdermal therapeutic system
CL2008002185A1 (es) Compuestos derivados de pirimidina, inhibidores de fosfatidilinositol-3-cinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades resapiratorias, alergias, inflamacion, cancer, entre otras enfermedades.
BRPI0607683A2 (pt) detecção de composição tópica
HN2003000090A (es) Compuestos que modulan la actividad de ppar
HK1198384A1 (en) Tricyclic compounds as anticancer agents
BR112012022243A2 (pt) terapias inibidoras de autografia baseadas em tioxantona para tratar câncer
CL2011000341A1 (es) Compuestos derivados de pirrolidinona sustituida, moduladores de la actividad de ar para la inhibicion de ntd; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de cancer, acne, hirsutismo, entre otras.
NO20080993L (no) Fremgangsmate for a forbedre arvakenhet
BRPI0711885A2 (pt) Aminotiazóis e seus usos
BRPI0509552A (pt) vacina de glicoproteìna mucinosa (muc-1)
BRPI0506970B8 (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
GEP20146001B (en) Cancer prophylactic/therapeutic agent

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2276 DE 19/08/2014.